Novartis says Signifor LAR drug helps control acromegaly disease
ZURICH (Reuters) - Swiss drugmaker Novartis said on Monday a final-stage trial of its Signifor LAR therapy allowed for greater disease control in patients with the endocrine disorder acromegaly than existing therapies.
Acromegaly is caused by a benign tumor in the pituitary gland that secretes excess growth hormone, and can lead to the enlargement of body parts, including the hands, feet and facial features.
Worldwide regulatory filings for pasireotide LAR in acromegaly are currently underway based on these results, Novartis said.
(Reporting by Alice Baghdjian)
- Poroshenko to seek ceasefire after 'very tough' talks with Putin |
- WHO shuts Sierra Leone lab after worker infected with Ebola
- 'Men in green' raise suspicions of east Ukrainian villagers
- Gaza ceasefire holding as focus turns to longer term |
- Libyan raids could herald bolder Arab action as U.S. wavers